alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION THAT IS EXTRACTED FROM
FORM 10-KSB FOR THE YEAR ENDED APRIL 30, 1999 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          APR-30-1999
<PERIOD-END>                               APR-30-1999
<CASH>                                         360,516
<SECURITIES>                                         0
<RECEIVABLES>                                   24,358
<ALLOWANCES>                                         0
<INVENTORY>                                     32,655
<CURRENT-ASSETS>                               443,148
<PP&E>                                          39,548
<DEPRECIATION>                                  21,989
<TOTAL-ASSETS>                               1,323,685
<CURRENT-LIABILITIES>                          112,033
<BONDS>                                        411,500
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        600
<COMMON>                                           700
<OTHER-SE>                                     798,852
<TOTAL-LIABILITY-AND-EQUITY>                 1,323,685
<SALES>                                        113,999
<TOTAL-REVENUES>                               113,999
<CGS>                                          103,802
<TOTAL-COSTS>                                  103,802
<OTHER-EXPENSES>                               752,459
<LOSS-PROVISION>                               373,342
<INTEREST-EXPENSE>                               2,457
<INCOME-PRETAX>                            (1,698,788)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,698,788)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,698,788)
<EPS-BASIC>                                    (.26)
<EPS-DILUTED>                                    (.26)


</TABLE>
exv10w2



 







Exhibit 10.2




			
	 	 	 
	 PLEASE SIGN & RETURN
	 	Non-Employee Director Stock Options

2003 Plan





Dear [Full Name]:




     Effective                      you have been granted a fully vested Non-qualified Option to purchase
up to [amount] shares of the common stock, par value $.25 per share, of Centex Corporation (the
“Company”) for $[price] per share (the “Option”). This Option is granted under the Centex
Corporation 2003 Equity Incentive Plan (as such plan may be amended from time to time, the “Plan”).
A copy of the Plan is available to you upon request to the Law Department during the term of this
Option. This Option will terminate upon the close of business on [7 years], unless earlier
terminated as described herein or in the Plan.



     If for any reason you cease to be a Director of the Company or an employee of at least one of
the employers in the group of employers consisting of the Company and its Affiliates, any portion
of this Option vested but not exercised by you on or before such date of cessation may be exercised
after such date only as provided in the Plan. However, if you retire from the Board of Directors
of the Company before all Shares subject to this Option have been exercised, then the exercise
period of the Option shall be extended to three years following your retirement, but in no event
longer than the seven-year life of this Option.



     You may pay the exercise price for any vested portion of this Option by electing to submit (by
actual delivery or attestation) shares owned by you for at least six months prior to exercise or
through other means specified in the Plan.



     The Company may cancel and revoke this Option and/or replace it with a revised option at any
time if the Company determines, in its good faith judgment, that this Option was granted to you in
error or that this Option contains an error. If the Company replaces this Option with a revised
option, then you will have all of the benefits conferred under the revised option, effective at
such time as the new option goes into effect.



     This Option is subject to the Plan, and the Plan will govern where there is any inconsistency
between the Plan and this Option. The provisions of the Plan are also provisions of this Option,
and all terms, provisions and definitions set forth in the Plan are incorporated in this Option and
made a part of this Option for all purposes. Capitalized terms used but not defined in this Option
will have the meanings assigned to such terms in the Plan. This Option has been signed in
duplicate by Centex Corporation and delivered to you, and (when you sign below) has been accepted
by you effective as of                     .



	 	 	 
	ACCEPTED

	 	CENTEX CORPORATION
	as of                     




	 	 
	 
	 

	 	 
	[Full Name]

	 	[Name]

[Title]
#### Lee *v.*Wagner.

[No. 17,029.

Filed April 5, 1943.]

*George 0. Cowan*and *Lawrence C. Ammon,*both of Indianapolis, for appellant.

*Lester C. Morris,*of Indianapolis, for appellee.

Dowell, J. —

This is an appeal from a judgment against the appellant on appellee’s complaint for money had and received. Answer and cross-complaint by appellant. The cause was tried to the court without a jury, resulting in finding for the appellee on his complaint and against the appellant on his answer and cross-complaint and judgment accordingly.

Appellant filed his motion for a new trial, which was overruled by the court,

*232Error assigned is the action of the trial court in overruling the motion for a new trial.

Appellee contends that appellant has failed to comply with Rule 2-17-F of Rules of the Supreme and Appellate Courts in that the motion for a new trial is not set out in appellant’s brief and that, under the rule above noted, no question for review or determination is ■presented to this court.

Appellee’s contention is correct. Neither the motion for a new trial, nor the substance thereof is to be found in the brief. No question is presented. *Fluck, Jr.*v. *Dahlberg*(1937), 103 Ind. App. 472, 8 N. E. (2d) 1008; *Henderson*v. *Country Pub. Co.*(1914), 57 Ind. App. 414, 107 N. E. 295; *Johnson*v. *State*(1938), 213 Ind. 659, 14 N. E. (2d) 96; *Peel*v. *Overstreet*(1921), 190 Ind. 290, 130 N. E. 113.

Judgment, therefore, is affirmed.

Blessing, C. J., not participating.

Note. — Reported in 47 N. E. (2d) 828.
[Federal Register Volume 75, Number 249 (Wednesday, December 29, 2010)]
[Notices]
[Page 82005]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-32824]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY


Proposed Subsequent Arrangement

AGENCY: Office of Nonproliferation and International Security, 
Department of Energy.

ACTION: Proposed subsequent arrangement.

-----------------------------------------------------------------------

SUMMARY: This notice is being issued under the authority of section 
131a. of the Atomic Energy Act of 1954, as amended (42 U.S.C. 2160). 
The Department is providing notice of a proposed subsequent arrangement 
under the Agreement for Cooperation Concerning Civil Uses of Nuclear 
Energy Between the Government of the United States of America and the 
Government of Canada and the Agreement for Cooperation Between the 
United States of America and the Government of the Republic of Korea 
Concerning Civil Uses of Atomic Energy.
    This subsequent arrangement concerns the retransfer of 29,887 kg of 
U.S.-origin natural uranium dioxide (88.00% U), 26,300 kg of which is 
uranium, from Cameco Corporation (Cameco) in Port Hope, Ontario, 
Canada, to Korea Nuclear Fuel Co. Ltd. in Yuson-Gu, Taejon, South 
Korea. The material, which is currently located at Cameco, will be 
transferred for fuel fabrication by Korea Nuclear Fuel Co. Ltd for 
final use in a civilian nuclear reactor power program by Korea Hydro & 
Nuclear Power Co. Ltd. The material was originally obtained by Cameco 
from Crowe Butte Resources pursuant to export license XSOU8798.
    In accordance with section 131a. of the Atomic Energy Act of 1954, 
as amended, it has been determined that this subsequent arrangement 
will not be inimical to the common defense and security.
    This subsequent arrangement will take effect no sooner than January 
13, 2011.

    Dated: December 20, 2010.

    For the Department of Energy.
Thomas P. D'Agostino,
Administrator, National Nuclear Security Administration.
[FR Doc. 2010-32824 Filed 12-28-10; 8:45 am]
BILLING CODE 6450-01-P
DIRECTORY•DESC•SRPID•CONSULTANT•PHASE•STATUS•TRANSMIT•SUBMITDATE•PACKNUM DGW2H10•DUPONT CHAMBERS WORKS DGW 2H10•NJD002385730•URS•REMED ACTION•PACKAGED•A•04/29/11•
# L_2018082DE.01001803.xml

| 26.3.2018 | DE | Amtsblatt der Europäischen Union | L 82/18 |
| --- | --- | --- | --- |

26.3.2018

DE

Amtsblatt der Europäischen Union

L 82/18

---

Berichtigung der Verordnung (EU) 2018/98 der Kommission vom 22. Januar 2018 zur Änderung der Anhänge II und III der Verordnung (EG) Nr. 1333/2008 des Europäischen Parlaments und des Rates sowie des Anhangs der Verordnung (EU) Nr. 231/2012 der Kommission in Bezug auf Calciumsorbat (E 203)

(
  Amtsblatt der Europäischen Union L 17 vom 23. Januar 2018
  )

Seite 28, Anhang, Nummer 2 zur Änderung des Anhangs III der Verordnung (EG) Nr. 1333/2008, Buchstabe c, Überschrift der Tabelle 2:

Anstatt:

„
  Sorbinsäure — Kaliums
  “

muss es heißen:

„
  Sorbinsäure — Kaliumsorbat
  “.

---
§ 1532.1110 How will a CAA or CWA conviction affect my eligibility to participate in Federal contracts, subcontracts, assistance, loans and other benefits? If you are convicted of any offense described in § 1532.1105, you are automatically disqualified from eligibility to receive any contract, subcontract, assistance, sub-assistance, loan or other nonprocurement benefit or transaction that is prohibited by a Federal department or agency under the Governmentwide debarment and suspension system (i.e. covered transactions under subpart A through I of 2 CFR part 180, or prohibited awards under 48 CFR part 9, subpart 9.4), if you: ( a ) Will perform any part of the transaction or award at the facility giving rise to your conviction (called the violating facility); and
( b ) You own, lease or supervise the violating facility.
#### § 2205.332 Fixed amount subawards.

Fixed amount subawards may be made in the manner and in amounts determined under the national service laws, as authorized by the Corporation, without respect to the Simplified Acquisition Threshold.
----

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Atlantis Business DevelopmentCorporation (the "Company") on Form 10-QSB for the quarter ended March 31, 2005,as filed with the Securities and Exchange Commission on the date hereof (the"Report"), I Christopher Dubeau, Chief Executive Officer of the Company,certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d)of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.

By: 

***/s/ Christopher Dubeau***

Christopher Dubeau

CEO

Dated:     June7, 2005

 

----
§ 1.97 Bonds. ( a ) The bond requirements under section 801(b) of the Federal Food, Drug, and Cosmetic Act may be satisfied by the owner or consignee executing, on the appropriate U.S. Customs and Border Protection form, a single-transaction or continuous bond, containing a condition for the redelivery of the merchandise or any part thereof upon demand of U.S. Customs and Border Protection and containing a provision for the performance of conditions as may legally be imposed for the relabeling or other action necessary to bring the article into compliance with the act or rendering it other than a food, drug, device, or cosmetic, in such manner as is prescribed for such bond in the customs regulations in force on the date of request for authorization. The bond shall be filed with U.S. Customs and Border Protection.
( b ) U.S. Customs and Border Protection may cancel the liability for liquidated damages incurred under the above-mentioned provisions of such a bond, if U.S. Customs and Border Protection receives an application for relief therefrom, upon the payment of a lesser amount or upon such other terms and conditions as shall be deemed appropriate under the law and in view of the circumstances, but U.S. Customs and Border Protection shall not act under this regulation unless the Food and Drug Administration division director is in full agreement with the action.
[85 FR 50782, Aug. 18, 2020]
§ 1316.22 Exemption. ( a ) Any person who is aggrieved by a disclosure of information in violation of subsection (c)(1) of Section 310 of the Controlled Substances Act (21 U.S.C. 830) may bring a civil action against the violator for appropriate relief.
( b ) Notwithstanding the provision of paragraph (a), a civil action may not be brought under such paragraph against investigative or law enforcement personnel of the Drug Enforcement Administration.
[54 FR 31670, Aug. 1, 1989]
Exhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Capitala Finance Corp. (the Company) for the annual period ended December 31, 2017, as filed with the Securities Exchange Commission on the date hereof (the Report), I, Stephen A. Arnall, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: 1.

          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and 2.

          The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: February 27, 2018 /s/ Stephen A. ArnallStephen A. Arnall Chief Financial Officer(Principal Financial and Accounting Officer) Capitala Finance Corp.
426 A.2d 152

#### Carolyn L. FOLCARELLI, Administratrix of the Estate of Dolores Regina Folcarelli, Deceased, and Anthony Folcarelli, Appellant, v. TRANSPORTATION SERVICES, INC. and Delpha L. Hager. Appeal of Carolyn L. FOLCARELLI.

Superior Court of Pennsylvania.

Submitted Dec. 6, 1979.

Filed Feb. 27, 1981.

*488Jerome B. Nulty, Souderton, for appellant.

Gilbert P. High, Jr., Norristown, for appellees.

Before BROSKY, WICKERSHAM and ROBERTS, JJ.*

*

 Justice SAMUEL J. ROBERTS of the Supreme Court of Pennsylvania, is sitting by designation.

WICKERSHAM, Judge:

' On the morning of September 3, 1975, Paul S. Hunsberger, Chief of Police of the Franconia Township Police Department, Montgomery County, was on routine duty. It was the first day of the new school year and the weather was clear. He received a radio call to respond to an accident on Indian Creek Road, Franconia Township and upon arrival learned that a school bus had come into contact with a twelve year old student by the name of Dolores Folcarelli. He observed that the school bus was parked or stopped much in the center of the highway and the child was in front of the left front wheel. She was unconscious and died two days later.

Thereafter, Carolyn L. Folcarelli, appellant herein, as administratrix of the estate of Dolores Regina Folcarelli, deceased, brought suit against Transportation Services, Inc. and Delpha L. Hager. The case proceeded to trial before a jury on April 18, 1978. The jury returned a verdict for the defendant following which post-verdict motions were filed by plaintiff’s administratrix, argued and denied by the trial court by Order of November 8, 1978. It was from that Order that an appeal was taken to this court.

> We have repeatedly advised the profession that an order refusing a new trial is interlocutory and is unappealable. Cf. *Bartkewich v. Billinger,*430 Pa. 207, 241 A.2d 916 (1968), and cases cited therein. The appeal should not be *489filed and may not be entertained until a final judgment is entered.

*Slagter v. Mix,*441 Pa. 272, 272 A.2d 885 (1971); *Waasdorp v. DiGiuseppe,*283 Pa.Super. 177, 423 A.2d 1047 (1980).1

Appeal quashed.

1

. Pa.R.A.P. 301(c) provides:

> A direction by the lower court that a specified judgment, sentence or other order shall be entered, unaccompanied by actual entry of the specified order in the docket, or a direction that a verdict of a jury be recorded or entered, or an order denying a motion for a new trial, does not constitute an appealable order. Any such order shall be reduced to judgment and docketed before an appeal is taken.

Although the appellee does not raise this issue, appealability of an order goes to the appellate court’s jurisdiction and may be raised *sua sponte. Williams v. Williams,*253 Pa.Super. 444, 385 A.2d 422 (1978); *Polascik v. Baldwin,*245 Pa.Super. 1, 369 A.2d 263 (1976); 42 Pa.C.S.A. § 704(b)(2).
Editorial Note on Part 106
Editorial Note: Nomenclature changes to part 106 appear at 81 FR 49895, July 29, 2016.

§ 106.94 Audit plans and procedures. ( a ) A manufacturer shall develop and follow a written audit plan that is available at the manufacturing facility for Food and Drug Administration inspection.
( b ) The audit plan shall include audit procedures that set out the methods the manufacturer uses to determine whether the facility is operating in accordance with current good manufacturing practice, with the quality control procedures that are necessary to ensure that an infant formula provides nutrients in accordance with sections 412(b) and (i) of the Federal Food, Drug, and Cosmetic Act, and in a manner designed to prevent adulteration of the infant formula.
( c ) The audit procedures shall include: ( 1 ) An evaluation of the production and in-process control system established under § 106.6(b) by: ( i ) Observing the production of infant formula and comparing the observed process to the written production and in-process control plan required under § 106.6(b);
( ii ) Reviewing records of the monitoring of points, steps, or stages where control is deemed necessary to prevent adulteration; and
( iii ) Reviewing records of how deviations from any specification at points, steps, or stages where control is deemed necessary to prevent adulteration were handled; and
( 2 ) A review of a representative sample of all records maintained in accordance with § 106.100(e) and (f).
```

[108th Congress Public Law 245]
[From the U.S. Government Printing Office]

[DOCID: f:publ245.108]

[[Page 118 STAT. 679]]

Public Law 108-245
108th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
  14 Chestnut Street in Liberty, New York, as the ``Ben R. Gerow Post 
       Office Building''. <<NOTE: June 25, 2004 -  [H.R. 3234]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION.

    The facility of the United States Postal Service located at 14 
Chestnut Street in Liberty, New York, shall be known and designated as 
the ``Ben R. Gerow Post Office Building''.

SEC. 2. REFERENCES.

    Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the facility referred to in section 1 
shall be deemed to be a reference to the ``Ben R. Gerow Post Office 
Building''.

    Approved June 25, 2004.

LEGISLATIVE HISTORY--H.R. 3234 (S. 1763):
---------------------------------------------------------------------------

CONGRESSIONAL RECORD:
                                                        Vol. 149 (2003):
                                    Oct. 28, considered and passed 
                                        House.
                                                        Vol. 150 (2004):
                                    June 9, considered and passed 
                                        Senate.

                                  <all>
```
#### § 1271.215 Recovery.

If you are an establishment that recovers HCT/Ps, you must recover each HCT/P in a way that does not cause contamination or cross-contamination during recovery, or otherwise increase the risk of the introduction, transmission, or spread of communicable disease through the use of the HCT/P.
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 1112 Introduced in Senate (IS)]

109th CONGRESS
  1st Session
                                S. 1112

   To make permanent the enhanced educational savings provisions for 
 qualified tuition programs enacted as part of the Economic Growth and 
                 Tax Relief Reconciliation Act of 2001.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 24, 2005

   Mr. Grassley (for himself, Mr. Baucus, Mr. Smith, Mr. Wyden, Mr. 
    McConnell, Mr. Jeffords, Mr. Lott, Mr. Schumer, Mr. Kerry, Mr. 
Bingaman, Mr. Rockefeller, Mrs. Lincoln, Ms. Landrieu, Mr. Corzine, Mr. 
 Talent, and Mr. Hagel) introduced the following bill; which was read 
             twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
   To make permanent the enhanced educational savings provisions for 
 qualified tuition programs enacted as part of the Economic Growth and 
                 Tax Relief Reconciliation Act of 2001.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``College 529 InvEST Act of 2005''.

SEC. 2. REPEAL OF THE SUNSET WITH RESPECT TO QUALIFIED TUITION PROGRAMS 
              EDUCATIONAL SAVINGS ENHANCEMENTS.

    Section 901 of the Economic Growth and Tax Relief Reconciliation 
Act of 2001 shall not apply to section 402 of such Act.
                                 <all>
```
#### § 1303.17 Abandonment of procurement quota.

Any manufacturer assigned a procurement quota for any basic class of controlled substance listed in schedule I or II pursuant to § 1303.12 may at any time abandon their right to manufacture all or any part of such quota by filing a notice of such abandonment with the UN Reporting and Quota Section, Diversion Control Division, Drug Enforcement Administration in the online Quota Management System. The Administrator may, in their discretion, allocate such amount among the other manufacturers in proportion to their respective quotas.

[88 FR 60141, Aug. 31, 2023]
```

```

# **Washington Aeromagnetic Maps and Data**

**  by  
 Carol Finn, K.C. Brenner, A. McCafferty, R. Kuck

 Open-File-Report 98-241    1998
**
```

```
§ 121.301 Records subject to the requirements of this subpart. ( a ) Except as provided by paragraph (b) of this section, all records required by subpart C of this part are subject to all requirements of this subpart.
( b ) The requirements of § 121.310 apply only to the written food defense plan.